Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
Fiocruz research observed that the drug Atazanavir was able to inhibit viral replication and to reduce the production of proteins that are related to the inflammatory process in the lungs in COVID-19.